SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Pasithea Therapeutics Corp.
Beneficial Ownership Disclosure
Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 9.99% in Pasithea Therapeutics Corp.'s common stock as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Pasithea Therapeutics Corp.
- As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 133,787 shares of Pasithea Therapeutics Corp. Common Stock.
- This ownership represents 9.99% of the total outstanding shares of the class.
- Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the shares held by the Master Fund.
- Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over all 133,787 shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or forward-looking statements that would indicate a positive or negative sentiment.
Industry Context
This filing is a standard disclosure of a significant ownership stake by an investment firm and its principal in a publicly traded company. It reflects an investment position rather than operational or strategic news from the issuer itself. Such filings are common in the investment landscape, providing transparency on large shareholder positions.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant ownership stake held by Armistice Capital, LLC and Steven Boyd, which could influence market perception or future corporate actions.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement, indicating the beneficial ownership percentage as of this date. |
| 02/14/2025 | Date the Schedule 13G/A filing was signed and submitted to the SEC. |
Keywords
Pasithea Therapeutics Corp., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Manager, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.